Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03839459 · ClinicalTrials.gov registry record · Phase 2
Denosumab for Smoldering Multiple Myeloma
A Phase 2 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03839459 is a Phase 2 study that has completed, run by University of Rochester. The registered enrollment target is 20 participants.
The verdict
NCT03839459, a Phase 2 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.
Interventions
- DRUG Denosumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-04-19 |
| Est. Completion | 2025-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03839459
The ClinicalTrials.gov registry entry for NCT03839459 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Denosumab is the first listed.
NCT03839459 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03839459 about?
NCT03839459 is a clinical study titled "Denosumab for Smoldering Multiple Myeloma". This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.
What is the current status of trial NCT03839459?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2019-04-19. Estimated completion is 2025-01-30.
What interventions are being tested in trial NCT03839459?
The interventions under investigation include: Denosumab (DRUG).
Who is sponsoring clinical trial NCT03839459?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.